38967078|t|The Gut Microbiota-Brain Axis: A New Frontier in Alzheimer's Disease Pathology.
38967078|a|Dr. Aloysius Alzheimer, a German neuropathologist and psychiatrist, recognized the primary instance of Alzheimer's disease (AD) for a millennium, and this ailment, along with its related dementias, remains a severe overall community issue related to health. Nearly fifty million individuals worldwide suffer from dementia, with Alzheimer's illness contributing to between 60 and 70% of the instances, estimated through the World Health Organization. In addition, 82 million individuals are anticipated to be affected by the global dementia epidemic by 2030 and 152 million by 2050. Furthermore, age, environmental circumstances, and inherited variables all increase the likelihood of acquiring neurodegenerative illnesses. Most recent pharmacological treatments are found in original hypotheses of disease, which include cholinergic (drugs that show affective cholinergic system availability) as well as amyloid-accumulation (a single drug is an antagonist receptor of Nmethyl D-aspartate). In 2020, the FDA provided approval on anti-amyloid drugs. According to mounting scientific data, this gut microbiota affects healthy physiological homeostasis and has a role in the etiology of conditions that range between obesity and neurodegenerative disorders like Alzheimer's. The microbiota-gut-brain axis might facilitate interconnection among gut microbes as well as the central nervous system (CNS). Interaction among the microbiota-gut system as well as the brain occurs through the "two-way" microbiota-gut-brain axis. Along this axis, the stomach as well as the brain develop physiologically and take on their final forms. This contact is constant and is mediated by numerous microbiota-derived products. The gut microbiota, for instance, can act as non-genetic markers to set a threshold for maintaining homeostasis or getting ill. The scientific community has conducted research and found that bowel dysbiosis and gastrointestinal tract dysregulation frequently occur in Alzheimer's disease (AD) patients. In this review, the effects of the microbiota- gut-brain axis on AD pathogenesis will be discussed.
38967078	49	68	Alzheimer's Disease	Disease	MESH:D000544
38967078	93	102	Alzheimer	Disease	MESH:D000544
38967078	183	202	Alzheimer's disease	Disease	MESH:D000544
38967078	204	206	AD	Disease	MESH:D000544
38967078	235	242	ailment	Disease	
38967078	267	276	dementias	Disease	MESH:D003704
38967078	393	401	dementia	Disease	MESH:D003704
38967078	408	427	Alzheimer's illness	Disease	MESH:D000544
38967078	611	619	dementia	Disease	MESH:D003704
38967078	774	801	neurodegenerative illnesses	Disease	MESH:D019636
38967078	984	1004	amyloid-accumulation	Disease	MESH:C000718787
38967078	1049	1068	Nmethyl D-aspartate	Chemical	MESH:D016202
38967078	1114	1121	amyloid	Disease	MESH:C000718787
38967078	1294	1301	obesity	Disease	MESH:D009765
38967078	1306	1333	neurodegenerative disorders	Disease	MESH:D019636
38967078	1339	1350	Alzheimer's	Disease	MESH:D000544
38967078	1978	1993	bowel dysbiosis	Disease	MESH:D064806
38967078	1998	2034	gastrointestinal tract dysregulation	Disease	MESH:D005770
38967078	2055	2074	Alzheimer's disease	Disease	MESH:D000544
38967078	2076	2078	AD	Disease	MESH:D000544
38967078	2080	2088	patients	Species	9606
38967078	2155	2157	AD	Disease	MESH:D000544
38967078	Negative_Correlation	MESH:D016202	MESH:C000718787

